S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
NASDAQ:RLMD

Relmada Therapeutics News Headlines

$19.86
+1.13 (+6.03%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$18.10
$19.92
50-Day Range
$16.93
$25.66
52-Week Range
$16.34
$40.00
Volume
101,934 shs
Average Volume
168,610 shs
Market Capitalization
$524.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.21
Get Relmada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Relmada Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RLMD
News Sentiment

0.31

0.32

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RLMD Articles
This Week

6

0

RLMD Articles
Average Week



Relmada Therapeutics (NASDAQ:RLMD) News Headlines Today

SourceHeadline
marketbeat.com logoRelmada Therapeutics (NASDAQ:RLMD) Raised to Buy at Zacks Investment Research
marketbeat.com - January 13 at 4:36 AM
MarketBeat logoRelmada Therapeutics (NASDAQ:RLMD) Shares Up 5.8%
americanbankingnews.com - January 14 at 3:20 PM
nasdaq.com logoNoteworthy Thursday Option Activity: UPST, RLMD, SAGE
nasdaq.com - January 13 at 5:45 PM
finance.yahoo.com logoWall Street Analysts See a 231% Upside in Relmada Therapeutics, Inc. (RLMD): Can the Stock Really Move This High?
finance.yahoo.com - January 12 at 11:42 AM
MarketBeat logoRelmada Therapeutics (NASDAQ:RLMD) Trading 7.3% Higher
americanbankingnews.com - December 23 at 12:41 PM
finance.yahoo.com logoRelmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
finance.yahoo.com - December 14 at 9:56 AM
reuters.com logoRLMD.O - Relmada Therapeutics Inc Profile | Reuters
reuters.com - December 10 at 6:17 PM
markets.businessinsider.com logoRelmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate
markets.businessinsider.com - December 9 at 10:20 AM
finance.yahoo.com logoRelmada Therapeutics to Present Data at the 60th Annual Meeting of the American College of Neuropsychopharmacology
finance.yahoo.com - December 1 at 9:59 AM
finance.yahoo.com logoIs Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
finance.yahoo.com - November 29 at 1:17 PM
finance.yahoo.com logoRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
finance.yahoo.com - November 11 at 6:08 PM
finance.yahoo.com logoRelmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021
finance.yahoo.com - November 4 at 8:13 AM
finance.yahoo.com logoSage, Biogen Plan to File Zuranolone NDA for MDD in 2022
finance.yahoo.com - October 20 at 1:55 PM
msn.com logoBRIEF-Relmada Therapeutics Provides Regulatory And Development Updates On Ongoing Late-Stage Clinical Program For Rel-1017
msn.com - October 4 at 6:59 PM
benzinga.com logoRelmada Therapeutics Dextromethadone Hydrochloride Received FDA Orphan Drug Designation on Monday for Treatment of Amyotrophic Lateral Sclerosis
benzinga.com - September 15 at 7:59 PM
finance.yahoo.com logoRelmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
finance.yahoo.com - August 10 at 7:25 PM
finance.yahoo.com logoRelmada Therapeutics to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 10, 2021
finance.yahoo.com - August 5 at 5:21 PM
nasdaq.com logoWhat You Need To Know About Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Investor Composition
nasdaq.com - August 2 at 10:10 PM
finance.yahoo.com logoDown 22.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Relmada Therapeutics, Inc. (RLMD)
finance.yahoo.com - July 30 at 12:53 PM
nasdaq.com logoRelmada Therapeutics Gains 6% On Positive Results Of REL-1017
nasdaq.com - July 27 at 12:09 PM
markets.businessinsider.com logoRelmada Therapeutics In-Licenses Psilocybin Program From Arbormentis
markets.businessinsider.com - July 22 at 7:59 PM
msn.com logoBRIEF-Relmada Therapeutics Announces The Acquisition Of Development And Commercial Rights To Novel Psilocybin And Derivates Program From Arbormentis Llc
msn.com - July 20 at 2:21 PM
finance.yahoo.com logoRelmada Therapeutics, Inc. (RLMD) stock forecast and price target
finance.yahoo.com - June 29 at 12:07 PM
finance.yahoo.com logoRelmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting
finance.yahoo.com - June 15 at 9:40 AM
finance.yahoo.com logoRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 12 at 6:49 PM
finance.yahoo.com logoRelmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021
finance.yahoo.com - May 6 at 5:28 PM
finance.yahoo.com logoRelmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting
finance.yahoo.com - April 29 at 8:32 AM
finance.yahoo.com logoRelmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit
finance.yahoo.com - April 28 at 9:42 AM
finance.yahoo.com logoRelmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021
finance.yahoo.com - April 27 at 8:57 AM
finance.yahoo.com logoRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
finance.yahoo.com - March 23 at 5:00 PM
finance.yahoo.com logoRelmada Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 23 at 2:40 PM
uk.finance.yahoo.com logoREL-1017 by Relmada Therapeutics: A NMDA Receptor Antagonists - Global Emerging Insight and Market Forecast Report 2021-2030 - ResearchAndMarkets.com
uk.finance.yahoo.com - March 18 at 8:43 PM
finance.yahoo.com logoRelmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021
finance.yahoo.com - March 18 at 8:43 PM
finance.yahoo.com logoRelmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference
finance.yahoo.com - March 11 at 12:10 PM
nasdaq.com logoNotable Thursday Option Activity: SPCE, CAR, RLMD
nasdaq.com - January 28 at 5:38 PM
nasdaq.com logoWill 2021 Continue To Be An Exciting Year For Relmada Therapeutics?
nasdaq.com - January 13 at 8:21 AM
finance.yahoo.com logoIs RLMD A Good Stock To Buy Now?
finance.yahoo.com - December 9 at 4:19 PM
finance.yahoo.com logoRelmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
finance.yahoo.com - December 7 at 9:12 AM
finance.yahoo.com logoWe Think Relmada Therapeutics (NASDAQ:RLMD) Can Afford To Drive Business Growth
finance.yahoo.com - December 3 at 8:42 AM
finance.yahoo.com logoRelmada Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 17 at 9:27 AM
markets.businessinsider.com logoRelmada Therapeutics Inc Registered Shs Neutral
markets.businessinsider.com - October 30 at 9:58 AM
nasdaq.com logoRelmada Therapeutics, Inc. Common Stock (RLMD)
nasdaq.com - October 23 at 12:02 AM
markets.businessinsider.com logoRelmada Therapeutics (RLMD) Stock
markets.businessinsider.com - August 1 at 6:39 PM
finance.yahoo.com logoOppenheimer: These 2 “Strong Buy” Stocks Are Poised to Surge by Over 80%
finance.yahoo.com - July 17 at 10:41 AM
finance.yahoo.com logoRelmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®
finance.yahoo.com - July 13 at 1:05 PM
www.marketwatch.com logoRelmada Therapeutics Inc.
www.marketwatch.com - July 9 at 7:25 PM
finance.yahoo.com logoWe're Not Worried About Relmada Therapeutics's (NASDAQ:RLMD) Cash Burn
finance.yahoo.com - June 26 at 8:11 AM
finance.yahoo.com logoHedge Funds Are Nibbling On Relmada Therapeutics, Inc. (RLMD)
finance.yahoo.com - June 24 at 5:57 PM
www.reuters.com logoBRIEF-Relmada Therapeutics Announces Notice Of Allowance For Patent In Canada
www.reuters.com - June 23 at 10:24 AM
finance.yahoo.com logoRelmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
finance.yahoo.com - June 9 at 9:21 AM
finance.yahoo.com logoRelmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
finance.yahoo.com - May 29 at 9:47 AM
Get Relmada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.